$MEIP
MEI Pharma, Inc.

2013 Q2 Form 10-Q Financial Statement

#000119312513208929 Filed on May 09, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.580M $1.230M $810.0K
YoY Change 79.55% 51.85% -21.36%
% of Gross Profit
Research & Development $1.650M $1.543M $1.490M
YoY Change 25.0% 3.56% 396.67%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $3.230M $2.768M $2.301M
YoY Change 46.82% 20.3% 73.01%
Operating Profit -$2.768M -$2.301M
YoY Change 20.3%
Interest Expense $20.00K $20.00K $30.00K
YoY Change -80.0% -33.33% 50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.220M -$2.750M -$2.270M
YoY Change 53.33% 21.15% 73.28%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.215M -$2.753M -$2.269M
YoY Change 53.02% 21.33% 72.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$191.4K -$183.1K -$930.3K
COMMON SHARES
Basic Shares Outstanding 17.12M shares 15.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.60M $24.20M $2.700M
YoY Change 474.19% 796.3% -44.9%
Cash & Equivalents $35.57M $24.17M $2.722M
Short-Term Investments
Other Short-Term Assets $500.0K $300.0K $500.0K
YoY Change 400.0% -40.0% 66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.03M $24.43M $3.300M
YoY Change 467.56% 640.21% -36.54%
LONG-TERM ASSETS
Property, Plant & Equipment $48.00K $41.00K $0.00
YoY Change 92.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $518.0K $520.0K $0.00
YoY Change 1972.0%
TOTAL ASSETS
Total Short-Term Assets $36.03M $24.43M $3.300M
Total Long-Term Assets $518.0K $520.0K $0.00
Total Assets $36.55M $24.95M $3.300M
YoY Change 473.47% 655.97% -36.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $537.0K $528.0K $400.0K
YoY Change -9.6% 32.0% -42.86%
Accrued Expenses $1.138M $1.254M $1.100M
YoY Change -3.56% 14.0% -8.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.675M $1.782M $1.500M
YoY Change -5.58% 18.8% -21.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.675M $1.782M $1.500M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.700M $1.800M $1.500M
YoY Change -4.17% 20.0% -21.05%
SHAREHOLDERS EQUITY
Retained Earnings -$96.30M -$93.08M
YoY Change 13.14%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.87M $23.17M $1.800M
YoY Change
Total Liabilities & Shareholders Equity $36.55M $24.95M $3.300M
YoY Change 473.47% 655.97% -36.54%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$3.215M -$2.753M -$2.269M
YoY Change 53.02% 21.33% 72.94%
Depreciation, Depletion And Amortization $20.00K $10.00K $0.00
YoY Change
Cash From Operating Activities -$2.760M -$2.630M -$2.280M
YoY Change 112.31% 15.35% 33.33%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$30.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$30.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.18M -60.00K 0.000
YoY Change 196.03% -100.0%
NET CHANGE
Cash From Operating Activities -2.760M -2.630M -2.280M
Cash From Investing Activities -10.00K -30.00K 0.000
Cash From Financing Activities 14.18M -60.00K 0.000
Net Change In Cash 11.41M -2.720M -2.280M
YoY Change 226.93% 19.3% 135.05%
FREE CASH FLOW
Cash From Operating Activities -$2.760M -$2.630M -$2.280M
Capital Expenditures -$10.00K -$30.00K $0.00
Free Cash Flow -$2.750M -$2.600M -$2.280M
YoY Change 111.54% 14.04% 33.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17116571 shares
CY2012Q4 meip Reverse Stock Split Ratio
ReverseStockSplitRatio
6 pure
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2722000
CY2013Q1 meip Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue
3452000
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
260000
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1810000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
136522 shares
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
23165000
CY2013Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
479000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3443000
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
83000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.79
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
660000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15036300 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4596361 shares
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
528000
CY2013Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93082000
CY2013Q1 us-gaap Assets
Assets
24947000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.39
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24947000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24167000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15036300 shares
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1254000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1782000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
495031 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2013Q1 us-gaap Assets Current
AssetsCurrent
24427000
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
3.12
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116247000
CY2013Q1 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M12D
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3858000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
146000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
4599000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
107000
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3416491 shares
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
594000
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85111000
CY2012Q2 us-gaap Assets
Assets
6373000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.64
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6373000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6202000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3416491 shares
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1180000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1774000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
143926 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2012Q2 us-gaap Assets Current
AssetsCurrent
6348000
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25000
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89710000
CY2012Q2 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y9M18D
dei Trading Symbol
TradingSymbol
MEIP
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25271000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y4M24D
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
us-gaap Operating Income Loss
OperatingIncomeLoss
-7990000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0062 pure
us-gaap Share Based Compensation
ShareBasedCompensation
766000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.00
us-gaap Profit Loss
ProfitLoss
-7971000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held.</font></p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7278000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
20000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17965000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.53 pure
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3557000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
114000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
351105 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y6M
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4433000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25271000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2596000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
271000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5777000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.61 pure
us-gaap Operating Expenses
OperatingExpenses
7990000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
500000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7941275 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0090 pure
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-66000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6027031 shares
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
10734
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Use of Estimates</b></font></p> <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could differ from those estimates.</font></p> </div>
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
37000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1136000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5047000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6191000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0090 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.45 pure
us-gaap Share Based Compensation
ShareBasedCompensation
389000
us-gaap Profit Loss
ProfitLoss
-5422000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.70
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
74000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.37
meip Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodTotalIntrinsicValue
meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2013-01
meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P4Y9M18D
meip Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
553000
meip Percentage Of Likelihood Of Income Tax Being Sustained
PercentageOfLikelihoodOfIncomeTaxBeingSustained
0.50 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3595000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4641000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.48 pure
us-gaap Operating Expenses
OperatingExpenses
6191000
us-gaap Financial Services Costs
FinancialServicesCosts
406000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2005820 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0132 pure
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
113000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1399692 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1139000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
137000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.58
CY2013Q1 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2015-06
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.63
CY2013Q1 meip Restricted Stock Unit Vesting Date
RestrictedStockUnitVestingDate
One third of the RSUs will vest on each of August 30, 2014, August 30, 2015 and August 30, 2016.
CY2012Q3 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
195756 shares
CY2000Q4 meip Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2000-12
CY2012Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
500000
us-gaap Operating Income Loss
OperatingIncomeLoss
-96364000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
112205000
us-gaap Gain Loss On Investments
GainLossOnInvestments
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59000
us-gaap Share Based Compensation
ShareBasedCompensation
3557000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-508000
us-gaap Profit Loss
ProfitLoss
-93082000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88218000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2919000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24167000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26327000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
260000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48537000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112464000
us-gaap Operating Expenses
OperatingExpenses
96364000
us-gaap Financial Services Costs
FinancialServicesCosts
406000
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
500000 shares
us-gaap License Costs
LicenseCosts
21500000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
528000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1188000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
665000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1254000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2768000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
186000
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-2753000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2013Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
15000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1225000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1543000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
2768000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15022854 shares
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2301000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
133000
CY2012Q1 us-gaap Profit Loss
ProfitLoss
-2269000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2012Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
32000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
811000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1490000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
2301000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2444791 shares

Files In Submission

Name View Source Status
0001193125-13-208929-index-headers.html Edgar Link pending
0001193125-13-208929-index.html Edgar Link pending
0001193125-13-208929.txt Edgar Link pending
0001193125-13-208929-xbrl.zip Edgar Link pending
d501547d10q.htm Edgar Link pending
d501547dex311.htm Edgar Link pending
d501547dex312.htm Edgar Link pending
d501547dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
meip-20130331.xml Edgar Link completed
meip-20130331.xsd Edgar Link pending
meip-20130331_cal.xml Edgar Link unprocessable
meip-20130331_def.xml Edgar Link unprocessable
meip-20130331_lab.xml Edgar Link unprocessable
meip-20130331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending